Abstract: A method of implementing administrative services for a compensation platform is disclosed. One or more interactive compensation representation views are generated based on an evaluation of mapping rules against a flexible ontology and current data state, the flexible ontology comprising customizable compensation components, relationships, and properties. One or more compensation representation views are dynamically updated in real-time in response to changes in compensation data, user context, or access permissions without requiring manual regeneration of the one or more compensation representations. The one or more interactive compensation representation views include a user interface element displayed in response to a user selection of compensation data, wherein the user interface element provides direct access to compensation information relevant to the selected compensation data without requiring a change to another screen or another user context.

Abstract: A method of generating customizable goal representation is disclosed. A request from a user to view a goal representation is received. A flexible goal ontology is accessed that comprises one or more goal entities, one or more goal relationships between the goal entities, or one or more goal properties, the one or more goal properties including one or more metadata attributes relating to the one or more goal entities. A set of mapping rules is obtained that defines mappings between one or more goals. The set of mapping rules is evaluated to assemble a customized goal representation tailored to the user. The customized goal representation is updated based on a revaluation of the mapping rules affected by changes to the one or more goal entities, the one or more goal relationships, or the one or more properties.

Abstract: Bi-specific chimeric antigen receptors (CARs) capable of binding to both CD19 and CD22 and immune cells expressing such. Also provided herein are therapeutic uses of such immune cells (e.g., CAR-T cells) for eliminating disease cells such as cancer cells.

Abstract: Disclosed herein are anti-SARS-CoV-2 spike protein antibodies and methods of using such for therapeutic and/or diagnostic purposes. Also provided herein are methods for producing such antibodies.

Abstract: Provided herein are engineered IL2 polypeptides and fusion proteins thereof. Also provided are methods of modulating an immune response by administering an engineered IL2 polypeptide or a fusion protein thereof. The engineered IL2 polypeptides and fusion proteins thereof demonstrate increased binding to IL2R?, decreased binding to IL2R?, or both.

Abstract: Disclosed herein are high affinity anti-CD22 antibodies and methods of using such for therapeutic and/or diagnostic purposes. Also provided herein are methods for producing such anti-CD22 antibodies.

Abstract: Disclosed herein are high affinity anti-CD19 antibodies and methods of using such for therapeutic and/or diagnostic purposes. Also provided herein are methods for producing such anti-CD19 antibodies. The anti-CD19 antibodies disclosed herein showed high stability as determined by thermal shift assays and bind different CD19 epitopes as FMC63. The anti-CD19 antibody clone used for developing immunotherapeutic agents such as tisagenlecleucel.